Comparison
Glutathione vs Tirzepatide
Side-by-side of Glutathione and Tirzepatide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Glutathione
Glutathione (GSH) is the body's primary intracellular antioxidant. Oral supplementation has variable bioavailability; sublingual, liposomal, and IV forms.
Tirzepatide
Tirzepatide for weight loss: dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound. SURMOUNT-1 showed 22.5% mean body-weight loss at 15 mg over 72 weeks.
Effects at a glance
Glutathione
- •Body's primary intracellular antioxidant; tripeptide of glutamate, cysteine, glycine
- •Oral bioavailability poor; sublingual, liposomal, IV more reliable
- •Richie 2014 trial showed body GSH store increases at 250-1000 mg/day for 6 months
- •NAC supplementation often more cost-effective indirect strategy
- •Modest signals in NAFLD, skin aging, immune support; weak in cardiovascular
Tirzepatide
- •Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
- •SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
- •Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
- •Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
- •GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
- •Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this
Side-by-side
| Attribute | Glutathione | Tirzepatide |
|---|---|---|
| Category | supplement | pharmaceutical |
| Also known as | GSH, L-glutathione, reduced glutathione | Mounjaro, Zepbound, LY3298176 |
| Half-life (hr) ↗ | 0.5 | 120 |
| Typical dose (mg) ↗ | 500 | 10 |
| Dosing frequency | daily, often divided | weekly |
| Routes | oral, sublingual, intravenous | subcutaneous |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 2 | 72 |
| Molecular weight | 307.32 | 4813.45 |
| Molecular formula | C10H17N3O6S | C225H348N48O68 |
| Mechanism | Tripeptide antioxidant; substrate for glutathione peroxidase (H2O2 reduction), GST (xenobiotic conjugation), glutaredoxin (redox signaling). GSH:GSSG ratio is the central cellular redox indicator. | Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits. |
| Legal status | OTC dietary supplement | Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound) |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement | Rx only (not a controlled substance) |
| Pregnancy | Insufficient data at supplemental doses; endogenous compound is safe | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 70-18-8 | 2023788-19-2 |
| PubChem CID | 124886 | 156588324 |
| Wikidata | Q116907 | Q105099794 |
Safety profile
Glutathione
Common side effects
- mild GI upset
Contraindications
- asthma (IV / inhaled forms specifically)
- active chemotherapy without oncologist guidance
Interactions
- chemotherapy agents: theoretical interference with GSH-depletion-dependent agents(moderate)
Tirzepatide
Common side effects
- nausea
- diarrhea
- vomiting
- constipation
- decreased appetite
- injection-site reactions
- fatigue
- abdominal pain
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
- severe gastroparesis
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- oral contraceptives: reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Glutathione comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Tirzepatide is the right call when one of the conditionals below applies.
- → If your priority is liver function, pick Glutathione.
- → If your priority is healthspan extension, pick Glutathione.
- → If your priority is metabolic health and glucose control, pick Tirzepatide.
- → If your priority is fat loss, pick Tirzepatide.
Edge case: If you want to avoid prescription-only, Glutathione is the more accessible choice.
Default choice: Glutathione. Lower friction to source, and broader goal coverage. Reach for Tirzepatide only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Glutathione and Tirzepatide?
Glutathione and Tirzepatide differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Glutathione or Tirzepatide?
Glutathione half-life is 0.5 hours; Tirzepatide half-life is 120 hours.
Can you stack Glutathione with Tirzepatide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper